Literature DB >> 35383871

Histological diversity of anti-PD1-induced colitis.

Stratigoula Sakellariou1, Evgenia Papathanasiou2, Marina Perdiki3, Maria Sotiropoulou4, Evangelia Zampeli2, Spyros Michopoulos2, Giorgos Bamias5, Ioanna Delladetsima6.   

Abstract

AIM: Histological data on anti-PD1-associated colitis are limited, while the colitis subtypes are still not clearly defined and different terms are being used. The aim of the study was to explore the histopathology of anti-PD1-induced colitis. METHODS AND
RESULTS: Colonic biopsies from 9 patients under anti-PD1 agents presenting diarrhea were examined. Histological evaluation revealed colitis of mild to moderate severity in almost all cases. Four distinct dominant histological patterns were identified with nearly the same incidence: Ulcerative colitis (UC)-like (n=2), GVHD-like (n=2), collagenous-like (n=3) and a mixed colitis pattern combining features of microscopic and UC-like colitis (n=2). The latter was additionally characterized by high crypt epithelium apoptosis and cryptitis with mixed inflammatory infiltrate. Thickening of the subepithelial band of collagen, detachment of the surface epithelium and increased apoptosis of the crypt epithelium were commonly encountered features, irrespective of colitis subtype. CD4/CD8 ratio was lower in the "combined" and higher in the GVHD-like subtype.
CONCLUSIONS: Anti-PD1-induced colitis is expressed by different patterns of injury which share distinct histological hallmarks harboring diagnostic value, while a "combined" colitis subtype is being established. The histological alterations are indicative of mucosa barrier damage after antΙ-PD1 treatment and its participation in the pathogenetic process. ©The Author(s) 2022. Open Access. This article is licensed under a Creative Commons CC-BY International License.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35383871     DOI: 10.14670/HH-18-456

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.130


  21 in total

1.  PD-1 inhibitor gastroenterocolitis: case series and appraisal of 'immunomodulatory gastroenterocolitis'.

Authors:  Raul S Gonzalez; Safia N Salaria; Caitlin D Bohannon; Aaron R Huber; Michael M Feely; Chanjuan Shi
Journal:  Histopathology       Date:  2016-12-20       Impact factor: 5.087

2.  Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review.

Authors:  Michael Collins; Emilie Soularue; Lysiane Marthey; Franck Carbonnel
Journal:  Clin Gastroenterol Hepatol       Date:  2020-01-31       Impact factor: 11.382

Review 3.  Systematic review: colitis associated with anti-CTLA-4 therapy.

Authors:  A Gupta; K M De Felice; E V Loftus; S Khanna
Journal:  Aliment Pharmacol Ther       Date:  2015-06-15       Impact factor: 8.171

4.  Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies.

Authors:  Jonathan H Chen; Maryam K Pezhouh; Gregory Y Lauwers; Ricard Masia
Journal:  Am J Surg Pathol       Date:  2017-05       Impact factor: 6.394

5.  Immunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy.

Authors:  Giorgos Bamias; Ioanna Delladetsima; Marina Perdiki; Spyros I Siakavellas; Dimitrios Goukos; George V Papatheodoridis; George L Daikos; Helen Gogas
Journal:  Cancer Invest       Date:  2017-05-26       Impact factor: 2.176

6.  Anti-PD1-induced collagenous colitis in a melanoma patient.

Authors:  Barouyr Baroudjian; Nelson Lourenco; Cécile Pagès; Ichrak Chami; Marianne Maillet; Philippe Bertheau; Martine Bagot; Jean-Marc Gornet; Céleste Lebbé; Matthieu Allez
Journal:  Melanoma Res       Date:  2016-06       Impact factor: 3.599

7.  Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities.

Authors:  Clélia Coutzac; Julien Adam; Emilie Soularue; Michael Collins; Antoine Racine; Charlotte Mussini; Lisa Boselli; Nyam Kamsukom; Christine Mateus; Mélinda Charrier; Lydie Cassard; David Planchard; Vincent Ribrag; Karim Fizazi; Yohann Loriot; Patricia Lepage; Jean-Yves Scoazec; Caroline Robert; Franck Carbonnel; Nathalie Chaput
Journal:  J Crohns Colitis       Date:  2017-10-01       Impact factor: 9.071

Review 8.  Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management.

Authors:  Marnix H Geukes Foppen; Elisa A Rozeman; Sandra van Wilpe; Cindy Postma; Petur Snaebjornsson; Johannes V van Thienen; Monique E van Leerdam; Michel van den Heuvel; Christian U Blank; Jolanda van Dieren; John B A G Haanen
Journal:  ESMO Open       Date:  2018-01-13

9.  Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?

Authors:  Vincent Ting Fung Cheung; Tarun Gupta; Anna Olsson-Brown; Sreedhar Subramanian; Sarah Christina Sasson; Jonathan Heseltine; Eve Fryer; Elena Collantes; Joseph J Sacco; Munir Pirmohamed; Alison Simmons; Paul Klenerman; Mark Tuthill; Andrew S Protheroe; Meenali Chitnis; Benjamin Peter Fairfax; Miranda Jane Payne; Mark Ross Middleton; Oliver Brain
Journal:  Br J Cancer       Date:  2020-05-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.